MORAb-003

DRUG3 trials

Sponsors

Morphotek, Eisai Co., Ltd.

Conditions

Epithelial Ovarian CancerNeoplasmsSolid Tumor

Phase 1

Safety, Tolerability and Pharmacokinetics of MORAb-003 in Subjects With Advanced Ovarian Cancer

CompletedNCT00428766

MorphotekEpithelial Ovarian Cancer

Start: 2005-06-30End: 2007-12-31Target: 24Updated: 2013-11-06

A Study of MORAb-003 in Patients With Solid Tumor

CompletedNCT01049061

Eisai Co., Ltd.Neoplasms, Solid Tumor

Start: 2010-01-31End: 2013-02-28Updated: 2020-06-11

Phase 2

An Open Label Extension Study of the Efficacy of MORAb-003

TerminatedNCT01018563

MorphotekEpithelial Ovarian Cancer

Start: 2010-01-13End: 2013-03-05Updated: 2021-12-08

Related Papers

A phase I study of farletuzumab, a humanized anti-folate receptor α monoclonal antibody, in patients with solid tumors

Investigational New Drugs2014-11-0927 citations